Guang Peng, M.D., Ph.D.
Department of Experimental Therapeutics, Division of Cancer Medicine
About Dr. Guang Peng
Guang Peng is a professor in the Department of Experimental Therapeutics at The University of Texas MD Anderson Cancer Center. She completed her Bachelor’s degree in medicine from Tongji Medical University, Wuhan, China. She received her PhD degree in biomedical sciences from the University of South Carolina, Columbia, SC, USA. The long-term goal of her research is to characterize and target molecular regulators of the mutational and dysfunctional DNA repair processes driving tumor evolution and immune responses.
Present Title & Affiliation
Primary Appointment
Professor, Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Regular Member, The University of Texas Graduate School of Biomedical Sciences (GSBS), Houston, TX
Dual/Joint/Adjunct Appointment
Regular Member, The University of Texas Graduate School of Biomedical Sciences (GSBS), Houston, TX
Research Interests
The overall goal of my laboratory is to understand the causes and consequences of genomic instability and the impact of genomic instability on evolvability and immune phenotypes of cancer cells in the evolutionary process of tumorigenesis. More specifically, by understanding and targeting the DNA repair network, our research aims to address two key questions: (1) Can we identify genetic alterations in the genome maintenance mechanisms that drive tumor evolution , particularly during the transition from premalignant lesions to cancer? (2) Can we identify targeted prevention/therapeutic strategies by modulating evolvability and immune phenotypes? Recent work in my laboratory explores the following directions:
1. Identify genetic alterations in the genome maintenance mechanisms that confers tumor evolvability and alters tumor immune phenotypes: We aim to investigate the novel functions of chromatin remodeling complex SWI/SNF, human nucleases/helicases DNA2 and mutational enzyme APOBEC3B in promoting tumorigenesis by both in vitro and in vivo studies, which may lead to identification of new strategy for early detection and intervention. We are also work to understand how environmental and endogenous factors reshape the landscape of cellular genome by targeting epigenetic regulatory machineries.
2. Discover novel agents targeting the genome maintenance mechanisms by genetic and chemical approaches: We aim to utilize chemical screening and bioinformatics’ tools as our drug-discovery platforms to systematically identify chemical compounds that target the DNA damage response and repair network. We will determine whether the reduction of cellular tolerance to endogenous DNA damage and altered immune responsiveness by modulating DNA repair process would open new avenues for cancer prevention and therapy.
3. Develop systems biology approaches to understand the dynamics of the genome maintenance mechanisms in tumor evolvability and immunoresponsiveness: We aim to utilize mathematical modeling, systems biology and molecular biology approaches to understand and target the DNA damage response and repair network. These new interdisciplinary approaches will offer a revolutionary conceptual framework to determine the compound effect of the DNA repair network rather than focusing on an individual repair gene’s function in tumor evolution and anti-tumor immunity.
Education & Training
Degree-Granting Education
| 2005 | University of South Carolina School of Medicine, Columbia, South Carolina, US, Biomedical Sciences, Ph.D |
| 2002 | Tongji Medical University, Wuhan, CN, MD |
Postgraduate Training
| 2006-2011 | Postdoc, Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2005-2006 | Postdoc, Cancer Biology, Fox Chase Cancer Center, Philadelphia, Pennsylvania |
Experience & Service
Academic Appointments
Professor, Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, 2023 - 2024
Associate Professor, Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2023
Assistant Professor, Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, 2011 - 2017
Instructor, Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2010 - 2011
Other Appointments/Responsibilities
Member, Admissions Committee, The University of Texas Graduate School of Biomedical Sciences (GSBS), Houston, TX, 2023 - Present
Member, Curriculum Committee, The University of Texas Graduate School of Biomedical Sciences (GSBS), Houston, TX, 2020 - 2023
Advisory Committee, DCPPS Diversity and Inclusion Initiative, Houston, TX, 2020 - Present
Advisory Committee, NCI R25E Cancer Prevention Education: Student Research Experience, Houston, TX, 2013 - Present
Advisory Committee, NCI R25T Postdoctoral and Predoctoral Fellowship in Cancer Prevention, Houston, TX, 2013 - Present
Advisory Committee, Cancer Prevention Research Training Program, Houston, TX, 2011 - Present
Institutional Committee Activities
Member, Faculty Senate Welfare Committee, 2023 - Present
Member, Senate Research Affairs Subcommittee, The Faculty Senate, 2022
Member, Employee Recognition Awards Review Board, Division of Cancer Prevention and Population Sciences (DCPPS), 2022
Member, The Department of Hematopoietic Biology &Malignancy (HBM) Chair Search Committee, 2021
Faculty Advisor, 2022 Genetics & Epigenetics (GE) Career Symposium Planning Committee, 2021 - 2022
Chair, Odyssey Committee, 2021 - 2022
Member, Faculty Senate, 2021 - Present
Member, Odyssey Committee, 2019 - 2021
Reviewer, Internal Review Study Section (INTEREST), 2017 - Present
Member, Biosafety Committee (IBC), 2016 - Present
Member, Faculty Academic Review Committee, 2015 - Present
Honors & Awards
| 2023 - 2024 | Breakthrough Award (Level 2)Partnering PI Award, Department of Defense (DOD)-Breast Cancer Research Program |
| 2023 - 2024 | Breakthrough Award (Level 2)Population Science and Prevention Studies-Partnering PI Award, Department of Defense (DOD)-Breast Cancer Research Program |
| 2022 - 2024 | Impact Award, Department of Defense (DOD)-Peer Reviewed Cancer Research Program |
| 2021 - 2024 | The Von Hippel-Lindau(VHL) Alliance Research Award |
| 2021 - 2024 | Translational Research Partnership Award, Department of Defense (DOD)- Kidney Cancer Research Program |
| 2020 | David H. Koch Center for Applied Research of Genitourinary Cancers Research Award |
| 2019 - 2021 | Exploration-Hypothesis Development Award, Department of Defense(DOD)- Tuberous Sclerosis Complex Research Program(TSCRP) |
| 2019 | Distinguished Doctorate Alumni Award, School of Medicine, University of South Carolina |
| 2019 | Kidney Cancer Association Advanced Discovery Award |
| 2018 - 2019 | Endometrial Cancer SPORE Research Development Award, NIH/NCI |
| 2015 - 2018 | Investigator-Initiated Research Award, Department of Defense (DoD) Ovarian Cancer Research Program |
| 2015 - 2018 | Wall of Science Award for Outstanding Scientific Research Awardee, Institutional Research Executive Commitee, MD Anderson Cancer Center |
| 2015 | Leading Mentor in Cancer Prevention, Honorable Mention |
| 2014 - 2017 | Susan G. Komen Career Catalyst Research Award |
| 2013 - 2015 | Ovarian Cancer SPORE Career Development Award, NIH/NCI |
| 2012 - 2015 | Landon Foundation-AACR Innovator Award for Cancer Prevention Research |
| 2012 | Texas Business Women Award, Texas Business Women Inc |
| 2011 - 2016 | Howard Temin Pathway to Independence Award, National Cancer Institute |
| 2010 | Trainee of the Quarter, University of Texas MD Anderson Cancer Center |
| 2009 | Trainee Excellence Award, University of Texas MD Anderson Cancer Center |
| 2008 | Oral Presentation Award, Society of Chinese Bioscientists in America Annual Symposia, Houston, TX |
| 2008 | Postdoctoral Fellowship, Susan G. Komen for the Cure Foundation |
| 2006 | Edward David Lustbader Prize, Fox Chase Cancer Center, Philadelphia, PA |
| 2006 | First Place in Oral Presentation, Fox Chase Cancer Center Postdoctoral and Graduate Student Research Conference, Philadelphia, PA |
| 2005 | First Place in Oral Presentation, Graduate Student Day, The Graduate School, University of South Carolina |
| 2005 | W. Morgan Newton Research Award, School of Medicine, University of South Carolina |
| 2004 | Best Student Poster Presentation, Annual South Carolina Alliance for Cancer Chemoprevention Symposium |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Yang Y, Wang J, Wan J, Cheng Q, Cheng Z, Zhou X, Wang O, Shi K, Wang L, Wang B, Zhu X, Chen J, Feng D, Liu Y, Jahan-Mihan Y, Haddock AN, Edenfield BH, Peng G, Hohenstein JD, McCabe CE, O'Brien DR, Wang C, Ilyas SI, Jiang L, Torbenson MS, Wang H, Nakhleh RE, Shi X, Wang Y, Bi Y, Gores GJ, Patel T, Ji B. PTEN Deficiency Induces an Extrahepatic Cholangitis-Cholangiocarcinoma Continuum via Aurora kinase A in Mice. J Hepatol 81(1):120-134, 2024. e-Pub 2024. PMID: 38428643.
- Ye Z, Xu S, Shi Y, Cheng X, Zhang Y, Roy S, Namjoshi S, Longo MA, Link TM, Schlacher K, Peng G, Yu D, Wang B, Tainer JA, Ahmed Z. GRB2 stabilizes RAD51 at reversed replication forks suppressing genomic instability and innate immunity against cancer. Nat Commun 15(1):2132, 2024. e-Pub 2024. PMID: 38459011.
- Li Y, Dobrolecki LE, Sallas C, Zhang X, Kerr TD, Bisht D, Wang Y, Awasthi S, Kaundal B, Wu S, Peng W, Mendillo ML, Lu Y, Jeter CR, Peng G, Liu J, Westin SN, Sood AK, Lewis MT, Das J, Yi SS, Bedford MT, McGrail DJ, Sahni N. PRMT blockade induces defective DNA replication stress response and synergizes with PARP inhibition. Cell Rep Med 4(12):101326, 2023. e-Pub 2023. PMID: 38118413.
- Liu XD, Zhang YT, McGrail DJ, Zhang X, Lam T, Hoang A, Hasanov E, Manyam G, Peterson CB, Zhu H, Kumar SV, Akbani R, Pilie PG, Tannir NM, Peng G, Jonasch E. SETD2 loss and ATR inhibition synergize to promote cGAS signaling and immunotherapy response in renal cell carcinoma. Clin Cancer Res 29(19):4002-4015, 2023. e-Pub 2023. PMID: 37527013.
- Wang R, Song S, Qin J, Yoshimura K, Peng F, Chu Y, Li Y, Fan Y, Jin J, Dang M, Dai E, Pei G, Han G, Hao D, Li Y, Chatterjee D, Harada K, Pizzi MP, Scott AW, Tatlonghari G, Yan X, Xu Z, Hu C, Mo S, Shanbhag N, Lu Y, Sewastjanow-Silva M, Fouad Abdelhakeem AA, Peng G, Hanash SM, Calin GA, Yee C, Mazur P, Marsden AN, Futreal A, Wang Z, Cheng X, Ajani JA, Wang L. Evolution of immune and stromal cell states and ecotypes during gastric adenocarcinoma progression. Cancer Cell 41(8):1407-1426.e9, 2023. e-Pub 2023. PMID: 37419119.
- Zhang, X, Yao, J, Li, X, Niu, N, Liu, Y, Hajek, RA, Peng, G, Westin, SN, Sood, AK, Liu, J. Targeting polyploid giant cancer cells potentiates a therapeutic response and overcomes resistance to PARP inhibitors in ovarian cancer. Science Advances 9(29), 2023. e-Pub 2023. PMID: 37478190.
- Mo Q, Yun S, Sallman DA, Vincelette ND, Peng G, Zhang L, Lancet JE, Padron E. Integrative molecular subtypes of acute myeloid leukemia. Blood Cancer J 13(1):71, 2023. e-Pub 2023. PMID: 37156780.
- An C, Pipia I, Ruiz AS, Argüelles I, An M, Wase S, Peng G. The molecular link between obesity and genomic instability in cancer development. Cancer Letters 555(555):216035, 2022. e-Pub 2022. PMID: 36502927.
- Fan Y, Li Y, Yao X, Jin J, Scott A, Liu B, Wang S, Huo L, Wang Y, Wang R, Pool Pizzi M, Ma L, Shao S, Sewastjanow-Silva M, Waters R, Chatterjee D, Liu B, Shanbhag N, Peng G, Calin GA, Mazur PK, Hanash SM, Ishizawa J, Hirata Y, Nagano O, Wang Z, Wang L, Xian W, McKeon F, Ajani JA, Song S. Epithelial SOX9 drives progression and metastases of gastric adenocarcinoma by promoting immunosuppressive tumour microenvironment. Gut. e-Pub 2022. PMID: 36002248.
- Wang L, Wang W, Beird HC, Cheng X, Fang H, Tang G, Toruner GA, Yin CC, You MJ, Issa GC, Borthakur G, Peng G, Khoury JD, Medeiros LJ, Tang Z. PPP1R7 Is a Novel Translocation Partner of CBFB via t(2;16)(q37;q22) in Acute Myeloid Leukemia. Genes (Basel) 13(8), 2022. e-Pub 2022. PMID: 36011278.
- Zhao M, Medeiros LJ, Wang W, Tang G, Jung HS, Sfamenos SM, Fang H, Toruner GA, Hu S, Yin CC, Lin P, Gu J, Peng G, You MJ, Khoury JD, Wang SA, Tang Z. Newly designed breakapart FISH probe helps to identify cases with true MECOM rearrangement in myeloid malignancies. Cancer Genet 262-263:23-29, 2022. e-Pub 2022. PMID: 34974290.
- Dong X, Song S, Li Y, Fan Y, Wang L, Wang R, Huo L, Scott A, Xu Y, Pizzi MP, Ma L, Wang Y, Jin J, Zhao W, Yao X, Johnson RL, Wang L, Wang Z, Peng G, Ajani JA. Loss of ARID1A activates mTOR signaling and SOX9 in gastric adenocarcinoma-rationale for targeting ARID1A deficiency. Gut 71(3):467-478, 2022. e-Pub 2022. PMID: 33785559.
- Ngoi NYL, Peng G, Yap TA. A Tale of Two Checkpoints: ATR Inhibition and PD-(L)1 Blockade. Annu Rev Med 73:231-250, 2022. e-Pub 2022. PMID: 34644155.
- Mo Q, Wan L, Schell MJ, Jim H, Tworoger SS, Peng G. Integrative Analysis Identifies Multi-Omics Signatures That Drive Molecular Classification of Uveal Melanoma. Cancers (Basel) 13(24), 2021. e-Pub 2021. PMID: 34944787.
- Hao D, He S, Harada K, Pizzi MP, Lu Y, Guan P, Chen L, Wang R, Zhang S, Sewastjanow-Silva M, Abdelhakeem A, Shanbhag N, Bhutani M, Han G, Lee JH, Zhao S, Weston B, Blum Murphy M, Waters R, Estrella JS, Roy-Chowdhuri S, Gan Q, Lee JS, Peng G, Hanash SM, Calin GA, Song X, Zhang J, Song S, Wang L, Ajani JA. Integrated genomic profiling and modelling for risk stratification in patients with advanced oesophagogastric adenocarcinoma. Gut 70(11):2055-2065, 2021. e-Pub 2021. PMID: 33334899.
- Yang RK, Toruner GA, Wang W, Fang H, Issa GC, Wang L, Quesada AE, Thakral B, Patel KP, Peng G, Liu S, Yin CC, Borthakur G, Tang Z, Wang SA, Miranda RN, Khoury JD, Medeiros LJ, Tang G. CBFB Break-Apart FISH Testing: An Analysis of 1629 AML Cases with a Focus on Atypical Findings and Their Implications in Clinical Diagnosis and Management. Cancers (Basel) 13(21), 2021. e-Pub 2021. PMID: 34771519.
- Pham MM, Ngoi NYL, Peng G, Tan DSP, Yap TA. Development of poly(ADP-ribose) polymerase inhibitor and immunotherapy combinations: progress, pitfalls, and promises. Trends Cancer 7(10):958-970, 2021. e-Pub 2021. PMID: 34158277.
- Tang, Z, Pilie, PG, Geng, C, Manyam, GC, Yang, G, Park, SH, Wang, D, Peng, S, Wu, C, Peng, G, Yap, TA, Corn, P, Broom, BM, Thompson, T. ATR inhibition induces CDK1-SPOP signaling and enhances anti-PD-L1 cytotoxicity in prostate cancer. Clinical Cancer Research 27(17):4898-4909, 2021. e-Pub 2021. PMID: 34168048.
- Han G, Yang G, Hao D, Lu Y, Thein K, Simpson BS, Chen J, Sun R, Alhalabi O, Wang R, Dang M, Dai E, Zhang S, Nie F, Zhao S, Guo C, Hamza A, Czerniak B, Cheng C, Siefker-Radtke A, Bhat K, Futreal A, Peng G, Wargo J, Peng W, Kadara H, Ajani J, Swanton C, Litchfield K, Ahnert JR, Gao J, Wang L. 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nat Commun 12(1):5606, 2021. e-Pub 2021. PMID: 34556668.
- Ye, Z, Xu, S, Shi, Y, Bacolla, A, Syed, A, Moiani, D, Tsai, C, Shen, Q, Peng, G, Leonard, P, Jones, DE, Wang, B, Tainer, J, Ahmed, Z. GRB2 enforces homology-directed repair initiation by MRE11. Science Advances 7(32), 2021. e-Pub 2021. PMID: 34348893.
- Yang B, Li X, Fu Y, Guo E, Ye Y, Li F, Liu S, Xiao R, Liu C, Lu F, Huang J, Qin T, Han L, Peng G, Mills GB, Sun C, Chen G. MEK Inhibition Remodels the Immune Landscape of Mutant KRAS Tumors to Overcome Resistance to PARP and Immune Checkpoint Inhibitors. Cancer Res 81(10):2714-2729, 2021. e-Pub 2021. PMID: 33589518.
- Ajani JA, Xu Y, Huo L, Wang R, Li Y, Wang Y, Pizzi MP, Scott A, Harada K, Ma L, Yao X, Jin J, Zhao W, Dong X, Badgwell BD, Shanbhag N, Tatlonghari G, Estrella JS, Roy-Chowdhuri S, Kobayashi M, Vykoukal JV, Hanash SM, Calin GA, Peng G, Lee JS, Johnson RL, Wang Z, Wang L, Song S. YAP1 mediates gastric adenocarcinoma peritoneal metastases that are attenuated by YAP1 inhibition. Gut 70(1):55-66, 2021. e-Pub 2021. PMID: 32345613.
- Wang R, Dang M, Harada K, Han G, Wang F, Pool Pizzi M, Zhao M, Tatlonghari G, Zhang S, Hao D, Lu Y, Zhao S, Badgwell BD, Blum Murphy M, Shanbhag N, Estrella JS, Roy-Chowdhuri S, Abdelhakeem AAF, Wang Y, Peng G, Hanash S, Calin GA, Song X, Chu Y, Zhang J, Li M, Chen K, Lazar AJ, Futreal A, Song S, Ajani JA, Wang L. Single-cell dissection of intratumoral heterogeneity and lineage diversity in metastatic gastric adenocarcinoma. Nat Med 27(1):141-151, 2021. e-Pub 2021. PMID: 33398161.
- Mo Q, Li R, Adeegbe DO, Peng G, Chan KS. Integrative multi-omics analysis of muscle-invasive bladder cancer identifies prognostic biomarkers for frontline chemotherapy and immunotherapy. Commun Biol 3(1):784, 2020. e-Pub 2020. PMID: 33335285.
- Wang L, Yang L, Wang C, Zhao W, Ju Z, Zhang W, Shen J, Peng Y, An C, Luu YT, Song S, Yap TA, Ajani JA, Mills GB, Shen X, Peng G. Inhibition of the ATM/Chk2 axis promotes cGAS/STING signaling in ARID1A-deficient tumors. J Clin Invest 130(11):5951-5966, 2020. e-Pub 2020. PMID: 33016929.
- Liang J, Wang L, Wang C, Shen J, Su B, Marisetty AL, Fang D, Kassab C, Jeong KJ, Zhao W, Lu Y, Jain AK, Zhou Z, Liang H, Sun SC, Lu C, Xu ZX, Yu Q, Shao S, Chen X, Gao M, Claret FX, Ding Z, Chen J, Chen P, Barton MC, Peng G, Mills GB, Heimberger AB. Verteporfin inhibits PD-L1 through autophagy and the STAT1-IRF1-TRIM28 signaling axis, exerting antitumor efficacy. Cancer Immunol Res 8(7):952-965, 2020. e-Pub 2020. PMID: 32265228.
- McGrail DJ, Garnett J, Yin J, Dai H, Shih DJH, Lam TNA, Li Y, Sun C, Li Y, Schmandt R, Wu JY, Hu L, Liang Y, Peng G, Jonasch E, Menter D, Yates MS, Kopetz S, Lu KH, Broaddus R, Mills GB, Sahni N, Lin SY. Proteome Instability Is a Therapeutic Vulnerability in Mismatch Repair-Deficient Cancer. Cancer Cell 37(3):371-386.e12, 2020. e-Pub 2020. PMID: 32109374.
- Wang B, Thapa S, Zhou T, Liu H, Li L, Peng G, Yu S. Cancer-related fatigue and biochemical parameters among cancer patients with different stages of sarcopenia. Support Care Cancer 28(2):581-588, 2020. e-Pub 2020. PMID: 31102055.
- Wang R, Song S, Harada K, Ghazanfari Amlashi F, Badgwell B, Pizzi MP, Xu Y, Zhao W, Dong X, Jin J, Wang Y, Scott A, Ma L, Huo L, Vicente D, Blum Murphy M, Shanbhag N, Tatlonghari G, Thomas I, Rogers J, Kobayashi M, Vykoukal J, Estrella JS, Roy-Chowdhuri S, Han G, Zhang S, Mao X, Song X, Zhang J, Gu J, Johnson RL, Calin GA, Peng G, Lee JS, Hanash SM, Futreal A, Wang Z, Wang L, Ajani JA. Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response. Gut 69(1):18-31, 2020. e-Pub 2020. PMID: 31171626.
- Hu G, Tu W, Yang L, Peng G, Yang L. ARID1A deficiency and immune checkpoint blockade therapy: From mechanisms to clinical application. Cancer Lett 473:148-155. e-Pub 2020. PMID: 31911080.
- Zou J, Qin W, Yang L, Wang L, Wang Y, Shen J, Xiong W, Yu S, Song S, Ajani JA, Lin SY, Mills GB, Yuan X, Chen J, Peng G. Genetic alterations and expression characteristics of ARID1A impact tumor immune contexture and survival in early-onset gastric cancer. Am J Cancer Res 10(11):3947-3972, 2020. e-Pub 2020. PMID: 33294279.
- Yin Y, Liu W, Shen Q, Zhang P, Wang L, Tao R, Li H, Ma X, Zeng X, Cheong JH, Song S, Ajani JA, Mills GB, Tao K, Peng G. The DNA endonuclease Mus81 regulates ZEB1 expression and serves as a target of BET4 inhibitors in gastric cancer. Mol Cancer Ther 18(8):1439-1450, 2019. e-Pub 2019. PMID: 31142662.
- Park YY, Jung SY, Jennings NB, Rodriguez-Aguayo C, Peng G, Lee SR, Kim SB, Kim K, Leem SH, Lin SY, Lopez-Berestein G, Sood AK, Lee JS. FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair. Carcinogenesis 40(7):936, 2019. e-Pub 2019. PMID: 31063534.
- Cao WM, Zheng YB, Gao Y, Ding XW, Sun Y, Huang Y, Lou CJ, Pan ZW, Peng G, Wang XJ. Comprehensive mutation detection of BRCA1/2 genes reveals large genomic rearrangements contribute to hereditary breast and ovarian cancer in Chinese women. BMC Cancer 19(1):551, 2019. e-Pub 2019. PMID: 31174498.
- Fang Y, McGrail DJ, Sun C, Labrie M, Chen X, Zhang D, Ju Z, Vellano CP, Lu Y, Li Y, Jeong KJ, Ding Z, Liang J, Wang SW, Dai H, Lee S, Sahni N, Mercado-Uribe I, Kim TB, Chen K, Lin SY, Peng G, Westin SN, Liu J, O'Connor MJ, Yap TA, Mills GB. Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy. Cancer Cell 35(6):851-867.e7, 2019. e-Pub 2019. PMID: 31185210.
- Lin T, Lin TC, McGrail DJ, Bhupal PK, Ku YH, Zhang W, Meng L, Lin SY, Peng G, Tsai RYL. Nucleostemin reveals a dichotomous nature of genome maintenance in mammary tumor progression. Oncogene 38(20):3919-3931, 2019. e-Pub 2019. PMID: 30692636.
- Shen J, Zhao W, Ju Z, Wang L, Peng Y, Labrie M, Yap TA, Mills GB, Peng G. PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness. Cancer Res 79(2):311-319, 2019. e-Pub 2019. PMID: 30482774.
- Chang L, Shen L, Zhou H, Gao J, Pan H, Zheng L, Armstrong B, Peng Y, Peng G, Zhou BP, Rosen ST, Shen B. ITCH nuclear translocation and H1.2 polyubiquitination negatively regulate the DNA damage response. Nucleic Acids Res 47(2):824-842, 2019. e-Pub 2019. PMID: 30517763.
- Yu Y, Pham N, Xia B, Papusha A, Wang G, Yan Z, Peng G, Chen K, Ira G. Dna2 nuclease deficiency results in large and complex DNA insertions at chromosomal breaks. Nature 564(7735):287-290, 2018. e-Pub 2018. PMID: 30518856.
- Jiang Y, Qian X, Shen J, Wang Y, Li X, Liu R, Xia Y, Chen Q, Peng G, Lin SY, Lu Z. Author Correction: Local generation of fumarate promotes DNA repair through inhibition of histone H3 demethylation. Nat Cell Biol 20(10):1226, 2018. e-Pub 2018. PMID: 29632342.
- Hsieh HJ, Zhang W, Lin SH, Yang WH, Wang JZ, Shen J, Zhang Y, Lu Y, Wang H, Yu J, Mills GB, G P. Systems biology approach reveals a link between mTORC1 and G2/M DNA damage checkpoint recovery. Nat Commun 9(1):3982, 2018. e-Pub 2018. PMID: 30266942.
- Shen J, Ju Z, Zhao W, Wang L, Peng Y, Ge Z, Nagel ZD, Zou J, Wang C, Kapoor P, Ma X, Ma D, Liang J, Song S, Liu J, Samson LD, Ajani JA, Li GM, Liang H, Shen X, Mills GB, G P. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nature Medicine 24(5):556-562, 2018. e-Pub 2018. PMID: 29736026.
- Sun C, Yin J, Fang Y, Chen J, Jeong KJ, Chen X, Vellano CP, Ju Z, Zhao W, Zhang D, Lu Y, Meric-Bernstam F, Yap TA, Hattersley M, O'Connor MJ, Chen H, Fawell S, Lin SY, Peng G, Mills GB. BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency. Cancer Cell 33(3):401-416.e8, 2018. e-Pub 2018. PMID: 29533782.
- Peng G, Mills GB. Surviving ovarian cancer: an affair between defective DNA repair and RB1. Clin Cancer Res 24(3):508-510, 2018. e-Pub 2018. PMID: 29191971.
- Zhang L, Peng Y, Peng G. Mismatch repair-based stratification for immune checkpoint blockade therapy. Am J Cancer Res 8(10):1977-1988, 2018. e-Pub 2018. PMID: 30416850.
- Wang C, Zou J, Ma X, Wang E, Peng G. Mechanisms and implications of ADAR-mediated RNA editing in cancer. Cancer Lett 411:27-34, 2017. e-Pub 2017. PMID: 28974449.
- Zhang L, Peng Y, Uray IP, Shen J, Wang L, Peng X, Brown PH, Tu W, Peng G. Natural product β-thujaplicin inhibits homologous recombination repair and sensitizes cancer cells to radiation therapy. DNA Repair (Amst) 60:89-101, 2017. e-Pub 2017. PMID: 29112893.
- Luo CW, Wang JY, Hung WC, Peng G, Tsai YL, Chang TM, Chai CY, Lin CH, Pan MR. G9a governs colon cancer stem cell phenotype and chemoradioresistance through PP2A-RPA axis-mediated DNA damage response. Radiother Oncol 124(3):395-402, 2017. e-Pub 2017. PMID: 28351524.
- Zhang L, Shen J, Yin Y, Peng Y, Wang L, Hsieh HJ, Shen Q, Brown PH, Tao K, Uray IP, Peng G. Identifying Cell Cycle Modulators That Selectively Target ARID1A Deficiency Using High-Throughput Image-Based Screening. SLAS Discov 22(7):813-826, 2017. e-Pub 2017. PMID: 28297605.
- Sun C, Fang Y, Yin J, Chen J, Ju Z, Zhang D, Chen X, Vellano CP, Jeong KJ, Ng PK, Eterovic AKB, Bhola NH, Lu Y, Westin SN, Grandis JR, Lin SY, Scott KL, Peng G, Brugge J, Mills GB. Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers. Sci Transl Med 9(392), 2017. e-Pub 2017. PMID: 28566428.
- Kumar S, Peng X, Daley J, Yang L, Shen J, Nguyen N, Bae G, Niu H, Peng Y, Hsieh HJ, Wang L, Rao C, Stephan CC, Sung P, Ira G, Peng G. Inhibition of DNA2 nuclease as a therapeutic strategy targeting replication stress in cancer cells. Oncogenesis 6(4):e319, 2017. e-Pub 2017. PMID: 28414320.
- Hsieh HJ, Peng G. Cellular responses to replication stress: implications in cancer biology and therapy. DNA Repair (Amst) 49:9-20, 2017. e-Pub 2017. PMID: 27908669.
- Peng Y, Scott P, Tao R, Wang H, Wu Y, Peng G. Dissect the Dynamic Molecular Circuits of Cell Cycle Control through Network Evolution Model. Biomed Res Int 2017:2954351, 2017. e-Pub 2017. PMID: 28466007.
- Yin Y, Shen Q, Zhang P, Tao R, Chang W, Li R, Xie G, Liu W, Zhang L, Kapoor P, Song S, Ajani J, Mills GB, Chen J, Tao K, Peng G. Chk1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN673 in gastric cancer. Am J Cancer Res 7(3):473-483, 2017. e-Pub 2017. PMID: 28401005.
- Zou J, Wang C, Ma X, Wang E, Peng G. APOBEC3B, a molecular driver of mutagenesis in human cancers. Cell Biosci 7:29, 2017. e-Pub 2017. PMID: 28572915.
- Mo W, Liu Q, Lin CC, Dai H, Peng Y, Liang Y, Peng G, Meric-Bernstam F, Mills GB, Li K, Lin SY. mTOR inhibitors suppress homologous recombination repair and synergize with PARP inhibitors via regulating SUV39H1 in BRCA-proficient triple-negative breast cancer. Clin Cancer Res 22(7):1699-712, 2016. e-Pub 2016. PMID: 26546619.
- Huang SJ, Tu, W, Ju ZL, Poage GM, Cai CR, Brewster A, Lin SY, Mills GB, Wang H, Peng G. A five-gene signature inferred from transcriptome profiling of homologous recombinant-mediated DNA repair predicts clinical outcome of patients with cancer. Jacobs Journal of Biomarkers 2(1):014, 2016. e-Pub 2016.
- Jiang Y, Qian X, Shen J, Wang Y, Li X, Liu R, Xia Y, Chen Q, Peng G, Lin SY, Lu Z. Local generation of fumarate promotes DNA repair through inhibition of histone H3 demethylation. Nat Cell Biol 17(9):1158-68, 2015. e-Pub 2015. PMID: 26237645.
- Shen J, Peng Y, Wei L, Zhang W, Yang L, Lan L, Kapoor P, Ju Z, Mo Q, IeM S, Uray IP, Wu X, Brown PH, Shen X, Mills GB, Peng G. ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors. Cancer Discov 5(7):752-67, 2015. e-Pub 2015. PMID: 26069190.
- Kapoor P, Bao Y, Xiao J, Espejo A, Yang L, Bedford MT, Peng G, Shen X. Phosphorylation-Dependent Enhancement of Rad53 Kinase Activity through the INO80 Chromatin Remodeling Complex. Mol Cell 58(5):863-9, 2015. e-Pub 2015. PMID: 25959398.
- Garrison JB, Ge C, Che L, Pullum DA, Peng G, Khan S, Ben-Jonathan N, Wang J, Du C. Knockdown of the inhibitor of apoptosis BRUCE sensitizes resistant breast cancer cells to chemotherapeutic agents. J Cancer Sci Ther 7(4):121-126, 2015. e-Pub 2015. PMID: 26191375.
- Kapoor P, Bao Y, Xiao J, Luo J, Shen J, Persinger J, Peng G, Ranish J, Bartholomew B, Shen X. Regulation of Mec1 kinase activity by the SWI/SNF chromatin remodeling complex. Genes Dev 29(6):591-602, 2015. e-Pub 2015. PMID: 25792597.
- Lee HJ, Lan L, Peng G, Chang WC, Hsu MC, Wang YN, Cheng CC, Wei L, Nakajima S, Chang SS, Liao HW, Chen CH, Lavin M, Ang KK, Lin SY, Hung MC. Tyrosine 370 phosphorylation of ATM positively regulates DNA damage response. Cell Res 25(2):225-36, 2015. e-Pub 2015. PMID: 25601159.
- Peng Y, Dai H, Wang E, Lin CC, Mo W, Peng G, Lin SY. TUSC4 functions as a tumor suppressor by regulating BRCA1 stability. Cancer Res 75(2):378-86, 2015. e-Pub 2015. PMID: 25480944.
- Zhang C, Peng G. Non-coding RNAs: an emerging player in DNA damage response. Mutat Res Rev Mutat Res 763:202-211, 2015. e-Pub 2015. PMID: 25795121.
- Liang J, Xu ZX, Ding Z, Lu Y, Yu Q, Werle KD, Zhou G, Park YY, Peng G, Gambello MJ, Mills GB. Myristoylation confers noncanonical AMPK functions in autophagy selectivity and mitochondrial surveillance. Nat Commun 14(6):7926, 2015. e-Pub 2015. PMID: 26272043.
- Zhang B, Wang E, Dai H, Shen J, Hsieh HJ, Lu X, Peng G. Phosphorylation of BRCT-Repeat Inhibitor of hTERT (BRIT1) Coordinates TopBP1 Recruitment and Amplifies ATR Signaling. J Biol Chem 289(49):34284-95, 2014. e-Pub 2014. PMID: 25301947.
- Peng G, Chun-Jen Lin C, Mo W, Dai H, Park YY, Kim SM, Peng Y, Mo Q, Siwko S, Hu R, Lee JS, Hennessy B, Hanash S, Mills GB, Lin SY. Genome-wide transcriptome profiling of homologous recombination DNA repair. Nat Commun 5:3361, 2014. e-Pub 2014. PMID: 24553445.
- Zhang Y, Wang H, Peng G. Identification of key links in the DNA repair network regulated by tumor suppressors PTEN and BRCA1 through maximum flow analysis. Far East Journal of Mathematical Sciences (FJMS) Special Volume 2013(Part VI):577-586, 2013. e-Pub 2013.
- Zhang B, Wang E, Dai H, Hu R, Liang Y, Li K, Wang G, Peng G, Lin SY. BRIT1 regulates p53 stability and functions as a tumor suppressor in breast cancer. Carcinogenesis 34(10):2271-80, 2013. e-Pub 2013. PMID: 23729656.
- Hu R, Wang E, Peng G, Dai H, Lin SY. Zinc Finger Protein 668 interacts with Tip60 to promote H2AX acetylation after DNA damage. Cell Cycle 12(13):2033-41, 2013. e-Pub 2013. PMID: 23777805.
- Meng L, Lin T, Peng G, Hsu JK, Lee S, Lin SY, Tsai RY. Nucleostemin deletion reveals an essential mechanism that maintains the genomic stability of stem and progenitor cells. Proc Natl Acad Sci U S A 110(28):11415-20, 2013. e-Pub 2013. PMID: 23798389.
- Wan G, Zhang X, Langley RR, Liu Y, Hu X, Han C, Peng G, Ellis LM, Jones SN, Lu X. DNA damage-induced nuclear export of precursor microRNAs is regulated by the ATM-AKT pathway. Cell Rep 3(6):2100-12, 2013. e-Pub 2013. PMID: 23791529.
- Wan G, Mathur R, Hu X, Liu Y, Zhang X, Peng G, Lu X. Long non-coding RNA ANRIL (CDKN2B-AS) is induced by the ATM-E2F1 signaling pathway. Cell Signal 25(5):1086-95, 2013. e-Pub 2013. PMID: 23416462.
- Wang H, Peng G. Mathematical Model of Dynamic Protein Interactions Regulating p53 Protein Stability for Tumor Suppression. Comput Math Methods Med 2013:358980, 2013. e-Pub 2013. PMID: 24454532.
- Park YY, Jung SY, Jennings NB, Rodriguez-Aguayo C, Peng G, Lee SR, Kim SB, Kim K, Leem SH, Lin SY, Lopez-Berestein G, Sood AK, Lee JS. FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair. Carcinogenesis 33(10):1843-53, 2012. e-Pub 2012. PMID: 22581827.
- Peng G, Dai H, Zhang W, Hsieh HJ, Pan MR, Park YY, Tsai RY, Bedrosian I, Lee JS, Ira G, Lin SY. Human nuclease/helicase DNA2 alleviates replication stress by promoting DNA end resection. Cancer Res 72(11):2802-13, 2012. e-Pub 2012. PMID: 22491672.
- Pan MR, Hsieh HJ, Dai H, Hung WC, Li K, Peng G, Lin SY. Chromodomain helicase DNA-binding protein 4 (CHD4) regulates homologous recombination DNA repair and its deficiency sensitizes cells to poly (ADP-ribose) polymerase (PARP) inhibitor treatment. J Biol Chem 287(9):6764-72, 2012. e-Pub 2012. PMID: 22219182.
- Hu R, Peng G, Dai H, Breuer EK, Stemke-Hale K, Li K, Gonzalez-Angulo AM, Mills GB, Lin SY. ZNF668 functions as a tumor suppressor by regulating p53 stability and function in breast cancer. Cancer Res 71(20):6524-6534, 2011. e-Pub 2011. PMID: 21852383.
- Zhang W, Peng G, Lin SY, Zhang P. DNA damage response is suppressed by high CDK1 activity in mitotic mammalian cells. J Biol Chem 286(41):35899-905, 2011. e-Pub 2011. PMID: 21878640.
- Pan MR, Peng G, Hung WC, Lin SY. Monoubiquitination of H2AX Protein Regulates DNA Damage Response Signaling. J Biol Chem 286(32):28599-607, 2011. e-Pub 2011. PMID: 21676867.
- Tian L, Peng G, Parant JM, Leventaki V, Drakos E, Zhang Q, Parker-Thornburg J, Shackleford TJ, Dai H, Lin SY, Lozano G, Rassidakis GZ, Claret FX. Essential roles of Jab1 in cell survival, spontaneous DNA damage and DNA repair. Oncogene 29(46):6125-37, 2010. e-Pub 2010. PMID: 20802511.
- Bellodi C, Krasnykh O, Haynes N, Theodoropoulou M, Peng G, Montanaro L, Ruggero D. Loss of function of the tumor suppressor DKC1 perturbs p27 translation control and contributes to pituitary tumorigenesis. Cancer Res 70(14):6026-35, 2010. e-Pub 2010. PMID: 20587522.
- Liang Y, Gao H, Lin SY, Peng G, Huang X, Zhang P, Goss JA, Brunicardi FC, Multani AS, Chang S, Li K. BRIT1/MCPH1 is essential for mitotic and meiotic recombination DNA repair and maintaining genomic stability in mice. PLoS Genet 6(1):e1000826, 2010. e-Pub 2010. PMID: 20107607.
- Peng G, Lin SY. The linkage of chromatin remodeling to genome maintenance: contribution from a human disease gene BRIT1/MCPH1. Epigenetics 4(7):457-61, 2009. e-Pub 2009. PMID: 19829069.
- Peng G, Lin SY. BRIT1/MCPH1 is a multifunctional DNA damage responsive protein mediating DNA repair-associated chromatin remodeling. Cell Cycle 8(19):3071-2, 2009. e-Pub 2009. PMID: 19755841.
- Peng G, Yim EK, Dai H, Jackson AP, Iv B, Pan MR, Hu R, Li K, Lin SY. BRIT1/MCPH1 links chromatin remodeling to DNA damage response. Nat Cell Biol 11(7):865-72, 2009. e-Pub 2009. PMID: 19525936.
- Yim EK, Peng G, Dai H, Hu R, Li K, Lu Y, Mills GB, Meric-Bernstam F, Hennessy BT, Craven RJ, Lin SY. Rak functions as a tumor suppressor by regulating PTEN protein stability and function. Cancer Cell 15(4):304-14, 2009. e-Pub 2009. PMID: 19345329.
- Rai R, Peng G, Li K, Lin SY. DNA damage response: the players, the network and the role in tumor suppression. Cancer Genomics Proteomics 4(2):99-106, 2007. e-Pub 2007. PMID: 17804872.
- Peng G, Wargovich MJ, Dixon DA. Anti-proliferative effects of green tea polyphenol EGCG on Ha-Ras-induced transformation of intestinal epithelial cells. Cancer Lett 238(2):260-70, 2006. e-Pub 2006. PMID: 16157446.
- Yoon A, Peng G, Brandenburger Y, Brandenburg Y, Zollo O, Xu W, Rego E, Ruggero D. Impairments in IRES-mediated translational control underlie X-linked dyskeratosis congenita. Science 312(5775):902-906, 2006. e-Pub 2006. PMID: 16690864.
- Peng G, Dixon DA, Muga SJ, Smith TJ, Wargovich MJ. Green tea polyphenol (-)-epigallocatechin-3-gallate inhibits cyclooxygenase-2 expression in colon carcinogenesis. Mol Carcinog 45(5):309-19, 2006. e-Pub 2006. PMID: 16508969.
Invited Articles
- Tu W, Wang H, Peng G. Synthetic lethality as a promising approach for targeted cancer prevention. Cancer and Clinical Research 2(a15), 2014. e-Pub 2014.
Editorials
- Peng G, Woodman SE, Mills GB. RADical response puts an exceptional responder in CHKmate: a synthetic lethal curative response to DNA-damaging chemotherapy?. Cancer Discov 4(9):988-90, 2014. PMID: 25185187.
- Peng G, Lin SY. Exploiting the homologous recombination DNA repair network for targeted cancer therapy. World J Clin Oncol 2(2):73-79, 2011. PMID: 21603316.
Abstracts
- Peng G, H-J H, Mills GB. Mathematical modeling reveals that G2/M checkpoint override creates a therapeutic vulnerability in mTOR-hyperactivated cancer. 2nd Exploring DNA repair pathways as targets for cancer therapy conference, Cancun, Mexico, 2017. e-Pub 2017.
- Peng G. Systems biology approaches to understand and target the DNA repair network. European Environmental Mutagenesis and Genomic Society 44th Annual Meeting, 2015, Prague, Czech Republic, 2015. e-Pub 2015.
- Wang E, Zhang B, Dai H, Lu X, Peng G. BRIT1 promotes ATR signaling through TOPBP1 recruitment to DNA repair sites. Cold Spring Harbor Laboratory, The Cell Cycle, 2014, New York City, NY, 2014. e-Pub 2014.
- Peng G. A molecular portrait of the homologous recombination DNA repair network via genome-wide transcriptome profiling. SCBA Satellite Meeting Genomic and Epigenomic Instability: Causes and Survival Mechanisms of Cancer, Nanjing, China, 2013. e-Pub 2013.
- Peng G, Mills G, S-Y L. A molecular portrait of the homologous recombination DNA repair network via genome-wide transcriptome profiling. 18th World Congress on Advances in Oncology and 16th International Symposium on Molecular Medicine, Crete, Greece, 2013. e-Pub 2013.
- Peng G, Mo W, Mills G B, S-Y L. A gene signature that predicts deficiency of homologous recombination DNA repair. Late breaking abstract. AACR Annual Meeting, Washington DC, 2013. e-Pub 2013.
- Peng G. Targeting cellular survival responses to replication stress in cancer. 3rd World Congress on Cancer Science & Therapy San Francisco, CA, 2013. e-Pub 2013.
- Peng G. Targeting cellular survival responses to replication stress as a novel approach for cancer prevention. AACR/JCA Joint Conference: Breakthrough in Basic and Translational Cancer Research, Maui, HI, 2013. e-Pub 2013.
- Peng G, Mo W, Mills G B, S-Y L. Gene signature to predict homologous recombination-mediated DNA repair deficiency. Keystone Joint Symposia: Genomic Instability and DNA repair, DNA replication and recombination, Banff, Alberta Canada, 2013. e-Pub 2013.
- Peng G. Targeting cellular survival responses to genomic instability in cancer. Society of Chinese Bioscientists in America the 14th International Symposium, Xi’an, China, 2013. e-Pub 2013.
- M-R P, S-Y L, Peng G. Chromatin remodeling as a new target for cancer chemoprevention. Frontiers in Cancer Prevention Research, Boston, MA, 2011. e-Pub 2011.
- Peng G, S-Y L. BRIT1/MCPH1 Links Chromatin Remodeling to DNA Damage Response. DLDCC Molecular Carcinogenesis/Cancer Biology Program Symposium, 2010. e-Pub 2010.
- Peng G, S-Y L. The Role of BRIT1 in Genome Maintenance and Cancer Suppression. International Cancer Biology Symposium, Taiwan, 2010. e-Pub 2010.
- Peng G, S-Y L. BRIT1/MCPH1 links chromatin remodeling to DNA damage response. Genetic Instability and Cancer Symposium, Houston,, 2009. e-Pub 2009.
- Peng G, S-Y L. The role of BRIT1/MCPH1 in chromatin remodeling, DNA damage response, and cancer. 8th International Conference of Anticancer Research, 2008. e-Pub 2008.
- S-Y L, Peng G. The role of BRIT1/MCpH1 in chromatin remodeling and DNA damage response. Maintenance of Genomic Stability Conference, Mexico, 2008. e-Pub 2008.
- Peng G, S-Y L. The role of BRIT1/MCpH1 in chromatin remodeling and DNA damage response. DNA Replication and Genomic Integrity Meeting 2008, San Diego, CA,, 2008. e-Pub 2008.
- Peng G, S-Y L. BRIT1/MCPH1 links chromatin remodeling to DNA damage response. The 2nd Meeting on Cellular Responses to DNA Damage, Boston, MA,, 2008. e-Pub 2008.
- Peng G, Wargovich MJ. Green tea polyphenol EGCG inhibits COX-2 expression in human colon cancer cells. AACR meeting, 2005. e-Pub 2005.
- Peng G, Wargovich MJ. Chemopreventive effects of green tea on COX-2 expression in human colon cancer cells. AACR meeting, 2004. e-Pub 2004.
Book Chapters
- Peng G, S-Y L. Emerging roles of BRIT1/MCPH1 in genome maintenance and tumor suppression. In: Tumor Suppressor. Nova Publishers, 2011.
- Peng G, S-Y L. A Novel DNA Damage Responsive Protein Dysfunctioned in Primary Microcephaly and Cancer. In: New Research on DNA Damage. Nova Publishers, 99-112, 2008.
Selected Presentations & Talks
Regional Presentations
- 2015. Understanding and targeting the DNA repair network for personalized cancer prevention. Conference. MDACC, Division of Cancer Prevention Faculty Retreat, US.
- 2015. Targeting SWI/SNF deficiency in human cancers: functionalizing cancer genomics for clinical applications. Conference. MDACC, Prostate Cancer Moon Shot Workshop ‘Targeting the DNA damage response for therapy’, US.
- 2012. Targeting Cellular Survival Responses to Replication Stress in Cancer. Conference. Division of Cancer Prevention Faculty Retreat, US.
- 2012. Targeting Cellular Survival Responses to Replication Stress in Cancer. Conference. CCSG Preparation Retreat for Clinical Cancer Prevention Program, US.
- 2012. Targeting the DNA repair network as a novel approach for cancer prevention. Conference. 2012 Texas Business Women Site Visit, US.
- 2012. Targeting replication stress as a novel approach for cancer prevention and therapy. Conference. Joint Retreat of Departments of Clinical Cancer Prevention and Carcinogenesis, US.
National Presentations
- 2022. Turning on DNA damage-dependent innate immune signaling to enhance the efficacy of immunotherapy. Invited. Chinese Biological Investigators Society (CBIS)13th biennial meeting. Las Vegas, NV, US.
- 2022. Targeting the DNA damage repair network to promote an innate immune response in ccRCC. Invited. Kidney Cancer Research Summit (KCRS). Philadelphia, PA, US.
- 2022. Turning on DNA damage-dependent innate immune signaling to enhance the efficacy of immunotherapy. Invited. Texas Conference on Genome Repair. San Antonio, TX, US.
- 2019. Moving beyond BRCAness in targeting DNA repair. Invited. Annual Global Academic Programs (GAP) Conference. Houston, TX, US.
- 2016. Stratification biomarkers and targeted therapeutics for BRCAness, QIAGEN (Suzhou) Translational Medicine Co. Ltd. Invited. Stratification biomarkers and targeted therapeutics for BRCAness, QIAGEN (Suzhou) Translational Medicine Co. Ltd. Suzhou, China, US.
- 2016. ARID1A mutations: mechanisms and clinical implications in precision cancer treatment. Invited. Union Hospital. Wuhan, China, US.
- 2015. Network flow as a systems biology approach to understand the DNA repair network in cancer. Invited. MAA general contributed paper session on interdisciplinary topics in mathematics, 2015 Joint mathematics meetings (Mathematical Association of America & American Mathematical Society). San Antonio, TX, US.
- 2014. BRIT 1 promotes ATR signaling through TOPBP1 recruitment to DNA repair sites. Invited. Cold Spring Harbor Laboratory. New York City, NY, US.
- 2013. Targeting the DNA repair network as a novel approach for cancer prevention. Invited. Breakthroughs in Basic and Translational Cancer Research. Maui, HI, US.
- 2009. BRIT1/MCPH1 links chromatin remodeling to DNA damage response. Invited. Baylor College of Medicine. Houston, TX, US.
International Presentations
- 2022. Transcriptomic mechanisms underlying the immune modulating function and therapeutic efficacy of PARP inhibitors. Invited. 18th Society of Chinese Bioscientists in America (SCBA) International Symposium. Boston, US.
- 2022. Turning on DNA damage-dependent innate immune signaling to enhance the efficacy of immunotherapy. Invited. Academia International Webinar on Cancer Research and Therapeutics. Virtual Conference, US.
- 2020. SWI/SNF-ARID1A deficiency in human cancers: functionalizing cancer genomics for clinical applications. Invited. Cholangiocarcinoma Foundation. Virtual Conference, US.
- 2019. ARID1A deficiency in human cancers: functionalizing cancer genomics for clinical applications. Conference. New England Biolab (NEB) Scientific Forum 2019-Next Generation Sequencing (NGS) Technologies and Applications Summit. Beijing, HK.
- 2018. Therapeutic vulnerabilities in ARID1A-deficient cancer. Invited. International Conference on Gastrointestinal Cancer and Therapeutics. San Francisco, US.
- 2018. Natural products as novel regulators of the DNA repair network in cancer prevention and therapy. Invited. 3rd World Congress on Medicinal Plants and Natural Products Research. Chicago, US.
- 2018. PARP inhibitors induce immunogenicity through transcriptome reprogramming independent of BRCAness. Invited. Journal of Molecular Cell Biology (JMCB) Symposium. Shanghai, CN.
- 2017. Dysfunctional ubiquitination process generates a therapeutic vulnerability in ARID1A-deficient cancers for DNA damage checkpoint inhibitors. Invited. 2nd Exploring DNA Repair Pathways as Targets for Cancer Therapy Conference. Cancun, MX.
- 2016. SWI/SNF mutations: translate genomic discoveries to precision treatment in cancer, the 1st International Young Scholars Forum of Tongji Hospital. Invited. SWI/SNF mutations: translate genomic discoveries to precision treatment in cancer, the 1st International Young Scholars Forum of Tongji Hospital. Wuhan, US.
- 2015. Systems biology approaches to understand and target the DNA repair network. Invited. European Environmental Mutagenesis and Genomic Society 44th Annual Meeting, 2015, Prague, Czech Republic. Prague, CZ.
- 2014. Targeting ARID1A deficiency in human cancer. Invited. Symposium of Translational Medicine Society of Oncology of Hubei Province, Tongji Hospital. Wuhan, CN.
- 2014. Systems biology approaches to understand and target the DNA repair network. Invited. International Symposium on DNA repair and space radiobiology. Lanzhou, CN.
- 2014. Targeting ARID1A deficiency in human cancer. Invited. 2014 Annual Congress of Translational Medicine Society of Chinese's Surgery Association & Laparoscopic Surgery Association of Hubei Province, Union Hospital. Wuhan, CN.
- 2013. Targeting cellular survival responses to replication stress in cancer. Invited. 3rd World Congress on Cancer Science & Therapy. San Francisco, US.
- 2013. A molecular portrait of the homologous recombination DNA repair network via genome-wide transcriptome profiling. Invited. 18th World Congress on Advances in Oncology and 16th International Symposium on Molecular Medicine, GR.
- 2013. A molecular portrait of the homologous recombination DNA repair network via genome-wide transcriptome profiling. Invited. SCBA Satellite Meeting Genomic and Epigenomic Instability, CN.
- 2013. Targeting cellular survival responses to genomic instability in cancer. Invited. Society of Chinese Bioscientists, CN.
Formal Peers
- 2023. STING: frenemy in anti-tumor immune responses and immunotherapy. Visiting. Houston, TX, US.
- 2023. Understanding and targeting the DNA damage response network. Visiting. Houston, TX, US.
- 2022. Turning on DNA damage-dependent innate immune signaling to enhance the efficacy of immunotherapy. Visiting. Houston, TX, US.
- 2022. Understanding and targeting the DNA damage response network: from a single-gene perspective to a systems biology approach. Visiting. Houston, TX, US.
- 2021. SWI/SNF-ARID1A deficiency in human cancers: functionalizing cancer genomics for clinical applications. Visiting. Houston, TX, US.
- 2021. SWI/SNF-ARID1A deficiency in human cancers: functionalizing cancer genomics for clinical applications. Visiting. Houston, TX, US.
- 2020. SWI/SNF-ARID1A deficiency in human cancers: functionalizing cancer genomics for clinical applications. Visiting. Houston, TX, US.
- 2020. SWI/SNF-ARID1A deficiency in human cancers: functionalizing cancer genomics for clinical applications. Invited. New Orleans, LA, US.
- 2020. SWI/SNF-ARID1A deficiency in human cancers: functionalizing cancer genomics for clinical applications. Visiting. Houston, TX, US.
- 2019. SWI/SNF-ARID1A deficiency in human cancers: functionalizing cancer genomics for clinical applications. Invited. Tampa, FL, US.
- 2018. Target the DNA repair network to modulate cancer mutability and anti-tumor immunity for cancer prevention and therapy. Visiting. Houston, TX, US.
- 2017. The DNA repair network in cancer evolvability and immunoresponsiveness. Invited. Atlanta, GA, US.
- 2016. Cell homeostasis: cell growth, differentiation, and cancer. Visiting. Houston, TX, US.
- 2016. Stratification biomarkers and targeted therapeutics for BRCAness. Visiting. Suzhou, CN.
- 2016. Systems biology approaches to understand and target the DNA repair network. Invited. Atlanta, GA, US.
- 2016. Functional genomics: target the SWI/SNF chromatin remodeling complex in cancer therapy. Invited. Houston, TX, US.
- 2015. Cell homeostasis: cell growth, differentiation, and cancer. Visiting. Houston, TX, US.
- 2015. Mutational process and tumor evolvability. Visiting. Houston, TX, US.
- 2015. Targeting ARID1A deficiency: functionalizing cancer genomic data for precision medicine. Invited. Prague, CZ.
- 2015. Diet and nutrition in cancer prevention. Visiting. Houston, TX, US.
- 2015. Genome-wide transcriptome profiling of homologous recombination DNA repair and insulin pathways: links between energy balance and genomic maintenance pathways. Visiting. Houston, TX, US.
- 2015. An introduction to breast cancer genetic testing and prevention. Visiting. Houston, TX, US.
- 2015. An introduction to breast cancer genetic testing and prevention. Visiting. Houston, TX, US.
- 2015. Understanding and targeting the DNA repair network for personalized cancer prevention. Visiting. Houston, TX, US.
- 2014. Targeting SWI/SNF deficiency in human cancers: functionalizing genomic data for clinical applications. Visiting. Houston, TX, US.
- 2014. Targeting ARID1A deficiency in human cancers: functionalizing genomic data for clinical applications. Visiting. Houston, TX, US.
- 2014. Characterize and target SWI/SNF-deficiency in ovarian cancer. Visiting. Houston, TX, US.
- 2013. The DNA repair network: biological insights and clinical applications. Invited. Crete, Crete, GR.
- 2012. The DNA repair network: biological insights and clinical applications. Invited, CA, US.
- 2012. The DNA repair network: from bench side mechanisms to bedside applications. Visiting, US.
- 2010. Understanding and targeting the DNA repair network in personalized cancer medicine. Invited. Houston, TX, US.
Grant & Contract Support
| Date: | 2023 - 2028 |
| Title: | Formation of Extrachromosomal DNA Fragments in Aging – Mechanisms, Regulation and Consequences |
| Funding Source: | Baylor College Of Medicine |
| Role: | Co-PI |
| Date: | 2023 - 2027 |
| Title: | Moving PARP inhibitors beyond BRCAness as immune modulating agents for TNBC prevention |
| Funding Source: | Department of Defense (DOD) |
| Role: | PI |
| ID: | BC220706P1 |
| Date: | 2023 - 2026 |
| Title: | Exploiting molecular origins and therapeutic implications of DNA damage-triggered innate immune response in breast cancer |
| Funding Source: | Department of Defense (DOD) |
| Role: | Partnering-Principal Investigator |
| ID: | W81XWH2210504_BC211174P1 |
| Date: | 2022 - 2026 |
| Title: | Modulate innate immune responses to Customize therapy in ARID1A-deficient gastric adenocarcinoma |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-PI |
| ID: | CA210439 |
| Date: | 2022 - 2027 |
| Title: | Mechanisms of radioresistance and strategies for radiosensitization in OCCC |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 5R01 CA181663-07 |
| Date: | 2022 - 2025 |
| Title: | Personalized therapy for patients with ARID1A deficient gastric adenocarcinoma (GAC) |
| Funding Source: | The Torrey Coast Foundation |
| Role: | Co-PI |
| Date: | 2021 - 2024 |
| Title: | Targeting the DNA damage repair network to promote an innate immune response in ccRCC |
| Funding Source: | Department of Defense (DOD) |
| Role: | Partnering-Principal Investigator |
| ID: | KC200150 |
| Date: | 2021 - 2026 |
| Title: | Transcriptomic mechanisms underlying the immune modulating function and therapeutic efficacy of PARP inhibitors |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA255074-01 |
| Date: | 2021 - 2024 |
| Title: | Identifying the determinants of clinical responses to PARP inhibitors in ovarian cancer immunotherapy |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-I |
| Date: | 2021 - 2024 |
| Title: | Immune modulation in von Hippel-Lindau disease by targeting the DNA damage response network |
| Funding Source: | VHL Alliance |
| Role: | Co-PI |
| Date: | 2020 - 2023 |
| Title: | Molecular Characterization of Interval Cancers |
| Funding Source: | Susan G. Komen Breast Cancer Foundation |
| Role: | Co-PI |
| ID: | SAC160064 |
| Date: | 2020 - 2021 |
| Title: | Molecular origins and therapeutic implications of tumor-intrinsic innate immune responses in renal cell carcinoma |
| Funding Source: | David H. Koch Center for Applied Research of Genitourinary Cancers |
| Role: | Co-PI |
| Date: | 2019 - 2021 |
| Title: | S-phase DNA damage response links genomic instability mechanisms to anti-tumor immunity in renal cell carcinoma |
| Funding Source: | The Kidney Cancer Association 2019 Advanced Discovery Award |
| Role: | Partnering-Principal Investigator |
| Date: | 2019 - 2022 |
| Title: | Maintenance of genome stability in TSC-deficient tumors |
| Funding Source: | Department of Defense (DOD) |
| Role: | PI |
| ID: | W81XWH1910459 |
| Date: | 2019 - 2021 |
| Title: | Novel formulation of synthetic retinoid for chemoprevention |
| Funding Source: | UHAND-DFI |
| Role: | Co-PI |
| ID: | 2019-00057076 |
| Date: | 2017 - 2022 |
| Title: | 2/2 U-HAND (University of Houston /MD Anderson) Program to Reduce Cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | P20CA221696 |
| Date: | 2017 - 2022 |
| Title: | UT MD Anderson Cancer Center SPORE in Ovarian Cancer-Project 1 |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1P50CA217685-01 |
| Date: | 2017 - 2020 |
| Title: | Identification of molecular mechanisms underlying Talazoparib and anti-PDL1 synergy |
| Funding Source: | Pfizer |
| Role: | PI |
| Date: | 2016 - 2019 |
| Title: | Mechanisms and targeting strategies for SWI/SNF mutations in cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-PI |
| ID: | RP160242 |
| Date: | 2015 - 2018 |
| Title: | Targeting ARID1A deficiency toward precision medicine in ovarian cancer |
| Funding Source: | Department of Defense (DOD) |
| Role: | PI |
| ID: | OC140431 |
| Date: | 2015 - 2018 |
| Title: | Targeting the APOEBC3B-induced mutator phenotype for preventing breast cancer |
| Funding Source: | Susan G. Komen Breast Cancer Foundation |
| Role: | PI |
| ID: | CCR14300500 |
| Date: | 2014 - 2018 |
| Title: | Role of DNA2 nuclease in cellular tolerance of replication stress and telomere maintenance-Implications for cancer biology and anticancer therapy |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-PI |
| ID: | RP140456 |
| Date: | 2014 - 2016 |
| Title: | Targeting the threshold of replication stress as a novel approach for pancreatic cancer prevention |
| Funding Source: | Duncan Family Institute |
| Role: | PI |
| Date: | 2013 - 2015 |
| Title: | Targeting ARID1A-deficiency in ovarian cancer |
| Funding Source: | MDACC Ovarian Cancer SPORE Career Development Award |
| Role: | PI |
| Date: | 2012 - 2014 |
| Title: | The role of nuclease/ helicase DNA2 in replication stress and tumorigenesis |
| Funding Source: | MDACC IRG Program |
| Role: | PI |
| ID: | 111576 |
| Date: | 2012 - 2014 |
| Title: | Targeting the DNA Repair Network as a Novel Approach for Cancer Research |
| Funding Source: | American Association for Cancer Research (AACR) |
| Role: | PI |
| ID: | 989258 |
| Date: | 2011 - 2016 |
| Title: | Understanding and Targeting DNA Repair Network in Cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | CA K99/R01 149186 |
| Date: | 2011 - 2018 |
| Title: | Investigating the roles of the DNA repair network in cancer prevention |
| Funding Source: | MD Anderson Cancer Center-Start-up Fund |
| Role: | PI |
| Date: | 2008 - 2010 |
| Title: | Genetic and Chemical Screens for Suppressors of Oct 4 Expression in Breast Cancer |
| Funding Source: | Susan G. Komen Breast Cancer Foundation |
| Role: | PI |
| ID: | KG070389 |
Patient Reviews
CV information above last modified June 24, 2025